Aripiprazole monohydrate (Abilify Maintena®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001447
English
Authors' recommendations:
Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged released suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/909
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Schizophrenia
- Piperazines
- Quinolones
- Delayed-Action Preparations
- Injections
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.